Foghorn Therapeutics Inc. (FHTX) bonds
FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 11/301% below fair value
$2.07+0.02 (+0.98%)
Close on Nov 13, 2026Market cap $122.93MP/E 29.6Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Foghorn Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2020
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Foghorn Therapeutics's 10-K/A for the period ended Dec 31, 2021
| Issue | Coupon | Amount issued | Carrying value |
|---|---|---|---|
| Term Loan A | 8.00% | $0 | $0 |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-K/A.
See a number that looks wrong?